Truist Financial Corp Cuts Holdings in Humana Inc. (NYSE:HUM)

Truist Financial Corp decreased its position in shares of Humana Inc. (NYSE:HUM) by 29.2% in the fourth quarter, HoldingsChannel reports. The firm owned 11,479 shares of the insurance provider’s stock after selling 4,733 shares during the quarter. Truist Financial Corp’s holdings in Humana were worth $5,255,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Dorsey & Whitney Trust CO LLC lifted its stake in Humana by 2.6% in the third quarter. Dorsey & Whitney Trust CO LLC now owns 817 shares of the insurance provider’s stock worth $397,000 after purchasing an additional 21 shares during the last quarter. First Financial Corp IN raised its stake in Humana by 7.2% in the fourth quarter. First Financial Corp IN now owns 343 shares of the insurance provider’s stock worth $157,000 after buying an additional 23 shares in the last quarter. First Trust Direct Indexing L.P. raised its stake in Humana by 0.8% in the third quarter. First Trust Direct Indexing L.P. now owns 2,926 shares of the insurance provider’s stock worth $1,424,000 after buying an additional 24 shares in the last quarter. Nvwm LLC raised its stake in Humana by 41.0% in the third quarter. Nvwm LLC now owns 86 shares of the insurance provider’s stock worth $42,000 after buying an additional 25 shares in the last quarter. Finally, Community Bank & Trust Waco Texas raised its stake in Humana by 3.7% in the third quarter. Community Bank & Trust Waco Texas now owns 841 shares of the insurance provider’s stock worth $408,000 after buying an additional 30 shares in the last quarter. Hedge funds and other institutional investors own 92.38% of the company’s stock.

Humana Price Performance

NYSE:HUM opened at $320.54 on Monday. Humana Inc. has a one year low of $298.61 and a one year high of $541.21. The company has a debt-to-equity ratio of 0.77, a quick ratio of 1.67 and a current ratio of 1.67. The firm has a market cap of $38.63 billion, a price-to-earnings ratio of 19.96, a PEG ratio of 1.86 and a beta of 0.49. The firm’s fifty day moving average is $324.12 and its two-hundred day moving average is $387.61.

Humana (NYSE:HUM) last posted its quarterly earnings results on Wednesday, April 24th. The insurance provider reported $7.23 EPS for the quarter, beating the consensus estimate of $6.12 by $1.11. Humana had a net margin of 1.82% and a return on equity of 17.76%. The company had revenue of $29.61 billion for the quarter, compared to analyst estimates of $28.52 billion. During the same period in the prior year, the company earned $9.38 earnings per share. The firm’s revenue was up 10.7% on a year-over-year basis. Research analysts expect that Humana Inc. will post 16.18 EPS for the current year.

Humana Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, July 26th. Shareholders of record on Friday, June 28th will be issued a $0.885 dividend. This represents a $3.54 annualized dividend and a yield of 1.10%. The ex-dividend date of this dividend is Friday, June 28th. Humana’s payout ratio is 22.04%.

Insider Buying and Selling at Humana

In other Humana news, Director Jorge S. Mesquita purchased 545 shares of the stock in a transaction on Tuesday, February 20th. The shares were bought at an average cost of $367.09 per share, with a total value of $200,064.05. Following the completion of the acquisition, the director now owns 2,578 shares in the company, valued at $946,358.02. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. 0.32% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on the stock. UBS Group reduced their price objective on shares of Humana from $334.00 to $326.00 and set a “neutral” rating for the company in a research note on Thursday, April 25th. Mizuho reduced their price objective on shares of Humana from $550.00 to $400.00 and set a “buy” rating for the company in a research note on Friday, January 26th. Cantor Fitzgerald reduced their price target on Humana from $391.00 to $360.00 and set a “neutral” rating on the stock in a research report on Thursday, April 25th. Bank of America reaffirmed a “neutral” rating and set a $342.00 price target (down from $470.00) on shares of Humana in a research report on Tuesday, April 2nd. Finally, Argus downgraded Humana from a “buy” rating to a “hold” rating in a research report on Wednesday, March 13th. Eleven investment analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Hold” and an average price target of $424.50.

Humana Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.